Notice of Proposed Sale · 144/A
EyePoint, Inc.
EYPTNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- EyePoint, Inc.
- Issuer CIK
- 0001314102
- SEC file number
- 000-51122
- Phone
- 6179265000
- Person for whose account securities are to be sold
- Lurker Nancy
- Relationships to issuer
- Officer
- Street
- 480 PLEASANT STREET
- Street (continued)
- SUITE C400
- City
- WATERTOWN
- State / country code
- MA
- Postal code
- 02472
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 1,235 | 15,820.00 | 84,841,298 | 07/22/2026 | NASDAQ | Fidelity Brokerage Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services
- Street
- 245 SUMMER STREET
- City
- Boston
- State / country code
- MA
- Postal code
- 02110
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 02/21/2022 | Stock Options | EYPT | 1,235 | N | 02/21/2022 | Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
sales may occur from from either Nancy Luker's individual account or the NANCY S LURKER 2020 IRRVOCABLE TRUST
Notice signature
- Notice date
- 07/22/2026
- Signed
- Jason Coleman as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Lurker Nancy
Company context
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).
Current securities
Recent company filings
- SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding EyePoint, Inc.Oct 27, 2026
- Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Other EventsOct 19, 2026
- Other EventsOct 19, 2026
- SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding EyePoint, Inc.Oct 7, 2026
- Other EventsSep 10, 2026